Vaccination with gp120-depleted HIV-1 plus immunostimulatory CpG oligodeoxynucleotides in incomplete Freund's adjuvant stimulates cellular and humoral immunity in rhesus macaques

Vaccine

Volumn 23, Issue 6, 2004, Pages 827-839

  Silvera, Peter ^a   Savary, Jay R ^b   Livingston, Virginia ^a   White, Jessica ^a   Manson, Kelledy H ^c   Wyand, Michael H ^c   Salk, Peter L ^d   Moss, Ronald B ^b,e   Lewis, Mark G ^a,f  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b Orchestra Therapeutics Inc   (United States)

^c Primedica Corporation   (United States)

^d SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^e San Diego   (United States)

^f BIOQUAL INC   (United States)

Author keywords

CpG ODN; HIV 1 vaccine; Immunogenicity

Indexed keywords

AMINO ACID; ANTIBODY; CAPSID PROTEIN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; EPITOPE; FREUND ADJUVANT; GAG PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; MATRIX PROTEIN; NUCLEOCAPSID PROTEIN; OLIGODEOXYNUCLEOTIDE DERIVATIVE; P24 ANTIBODY; P6 PROTEIN; PROTEIN P2; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG TOLERABILITY; EMULSION; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSTIMULATION; MACACA; MEASUREMENT; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; T LYMPHOCYTE; VACCINATION; VIRUS CAPSID; VIRUS NUCLEOCAPSID;

AIDS VACCINES; ANIMALS; ANTIBODY FORMATION; CPG ISLANDS; FREUND'S ADJUVANT; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; IMMUNITY, CELLULAR; INTERFERON TYPE II; MACACA MULATTA; VACCINATION;

EID: 8144226080     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.06.045     Document Type: Article

References (62)

1. D.H. Barouch, S. Santra, and J.E. Schmitz Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination Science 290 5491 2000 486 492
2. R.R. Amara, F. Villinger, and J.D. Altman Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine Science 292 5514 2001 69 74
3. J.W. Shiver, T.M. Fu, and L. Chen Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity Nature 415 6869 2002 331 335
4. F. Verrier, S. Burda, and R. Belshe A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates J. Virol. 74 21 2000 10025 10033
5. B. Gaschen, J. Taylor, and K. Yusim Diversity considerations in HIV-1 vaccine selection Science 296 5577 2002 2354 2360
6. T. Lehner, L. Bergmeier, Y. Wang, L. Tao, and E. Mitchell A rational basis for mucosal vaccination against HIV infection Immunol. Rev. 170 1999 183 196
7. R.B. Moss, M.R. Wallace, and P. Lanza In vitro p24 antigen stimulated lymphocyte proliferation and β-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (REMUNE™) Clin. Diagn. Lab. Immunol. 5 3 1998 308 312
8. R.B. Moss, W. Giermakowska, and P. Lanza Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 Immunogen REMUNE™) in human immunodeficiency virus type-1 seropositive subjects Viral Immunol. 10 4 1997 221 228
9. ®) as a therapeutic vaccine in the treatment of HIV infection Expert Rev. Vaccines 2 6 2003 89 101
10. F. Valentine, V. De Gruttola, and REMUNE 816 Study Team Immunological and virological evaluations of the effects of HAART compared to HAART plus an inactivated HIV immunogen after 32 weeks Proceedings of the Sixth Conference on Retroviruses and Opportunistic Infections Chicago, IL 1999 [Abstract #346]
11. R.B. Moss, W. Giermakowska, M.R. Wallace, J. Savary, F. Jensen, and D.J. Carlo T-helper-cell proliferative responses to whole-killed human immunodeficiency virus type 1 (HIV-1) and p24 antigens of different clades in HIV-1-infected subjects vaccinated with HIV-1 immunogen (Remune) Clin. Diagn. Lab. Immunol. 7 5 2000 724 727
12. 6/L CD4 cell counts: a randomized controlled trial J. Am. Med. Assoc. 284 17 2000 2193 2202
13. J.L. Turner, J.R. Kostman, and A. Aquino The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cell counts and HIV-specific immunity in a double-blind, randomized, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs HIV Med. 2 2 2001 68 77
14. R.S. Chu, O.S. Targoni, A.M. Krieg, P.V. Lehmann, and C.V. Harding CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity J. Exp. Med. 186 10 1997 1623 1631
15. R.B. Moss, J.P. Diveley, F.C. Jensen, and D.J. Carlo In vitro immune function after vaccination with an inactivated, gp120-depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides Vaccine 18 11-12 2000 1081 1087
16. R.B. Moss, J. Diveley, F.C. Jensen, E. Gouveia, and D.J. Carlo Human immunodeficiency virus (HIV)-specific immune responses are generated with the simultaneous vaccination of a gp120-depleted, whole-killed HIV-1 immunogen with cytosine-phosphorothioate-guanine dinucleotide immunostimulatory sequences of DNA J. Hum. Virol. 4 1 2001 39 43
17. R.B. Moss, J.R. Savary, J.P. Diveley, F. Jensen, and D.J. Carlo Maternal and newborn immunization with a human immunodeficiency virus-1 immunogen in a rodent model Immunology 106 2002 549 553
18. R.B. Moss, J. Diveley, F.C. Jensen, E. Gouveia, J. Savary, and D.J. Carlo HIV-specific CD4+ and CD8+ immune responses are generated with a gp120-depleted, whole-killed HIV-1 immunogen with CpG immunostimulatory sequences of DNA J. Interferon Cytokine Res. 20 12 2000 1131 1137
19. T. Sparwasser, R.M. Vabulas, B. Villmow, G.B. Lipford, and H. Wagner Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins Eur. J. Immunol. 30 12 2000 3591 3597
20. E.G. Rhee, S. Mendez, and J.A. Shah Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection J. Exp. Med. 195 12 2002 1565 1573
21. T.Y. Kim, H.J. Myoung, and J.H. Kim Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection Cancer Res. 62 24 2002 7234 7240
22. M. Roman, E. Martin-Orozco, and J.S. Goodman Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants Nat. Med. 3 8 1997 849 854
23. L. Deml, R. Schirmbeck, J. Reimann, H. Wolf, and R. Wagner Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp160 envelope proteins Clin. Chem. Lab. Med. 37 3 1999 199 204
24. A.M. Krieg, and H.L. Davis Enhancing vaccines with immune stimulatory CpG DNA Curr. Opin. Mol. Ther. 3 1 2001 15 24
25. M. Ayash-Rashkovsky, Z. Weisman, J. Diveley, R.B. Moss, Z. Bentwich, and G. Borkow Generation of Th1 immune responses to inactivated, gp120-depleted HIV-1 in mice with a dominant Th2 biased immune profile via immunostimulatory oligonucleotides - relevance to AIDS vaccines in developing countries Vaccine 20 21-22 2002 2684 2692
26. H. Hemmi, O. Takeuchi, and T. Kawai A Toll-like receptor recognizes bacterial DNA Nature 408 6813 2000 740 745
27. A.M. Krieg CpG motifs: the active ingredient in bacterial extracts? Nat. Med. 9 7 2003 831 835
28. H.L. Davis, I.I. Suparto, and R.R. Weeratna CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans Vaccine 18 18 2000 1920 1924
29. D.M. Klinman CpG DNA as a vaccine adjuvant Expert Rev. Vaccines 2 2 2003 305 315
30. J.L. Turner, J.R. Kostman, and A. Aquino The effects of an HIV-1 immunogen (REMUNE™) on viral load, CD4 cell counts, and HIV-specific immunity in a double-blind, randomized, adjuvant-controlled subset study in infected subjects regardless of concomitant antiviral drugs HIV Med. 2 2 2001 68 77
31. C. Prior, P. Bay, and B. Ebert Process development for the manufacture of inactivated HIV-1 Pharm. Technol. 8 4 1995 25 35
32. P. Silvera, M.W. Richardson, and J. Greenhouse Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein J. Virol. 76 8 2002 3800 3809
33. HIV helper-T cell epitopes. In: Korber BT, Brander C, Haynes BF, editors. HIV Molecular Immunology Database 2000. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory. p. III-A-3-III-A-8.
34. S.L. Adams, R.A. Biti, and G.J. Steward T-cell response to HIV in natural infection: optimized culture conditions for detecting responses to Gag peptides J. AIDS 15 1997 257 263
35. E.S. Rosenberg, J.M. Billingsley, and A.M. Caliendo Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia Science 278 5342 1997 1447 1450
36. H. Gahery-Segard, G. Pialoux, and B. Charmeteau Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine J. Virol. 74 4 2000 1694 1703
37. M. Mata, and Y. Paterson Th1 T cell responses to HIV-1 Gag protein delivered by a Listeria monocytogenes vaccine are similar to those induced by endogenous listerial antigens J. Immunol. 163 3 1999 1449 1456
38. S.M. Donahoe, W.J. Moretto, and R.V. Samuel Direct measurement of CD8+ T cell responses in macaques infected with simian immunodeficiency virus Virology 272 2 2000 347 356
39. K.V. Komanduri, S.M. Donahoe, and W.J. Moretto Direct measurement of CD4+ and CD8+ T-cell responses to CMV in HIV-1-infected subjects Virology 279 2 2001 459 470
40. K.L. Rock, S. Gamble, and L. Rothstein Presentation of exogenous antigen with class I major histocompatibility complex molecules Science 249 4971 1990 918 921
41. C.V. Harding, and R. Song Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules J. Immunol. 153 11 1994 4925 4933
42. H.T. Maecker, H.S. Dunn, and M.A. Suni Use of overlapping peptide mixtures as antigens for cytokine flow cytometry J. Immunol. Methods 255 1-2 2001 27 40
43. H.T. Maecker, S.A. Ghanekar, M.A. Suni, X.S. He, L.J. Picker, and V.C. Maino Factors affecting the efficiency of CD8+ T cell cross-priming with exogenous antigens J. Immunol. 166 12 2001 7268 7275
44. Moss RB, Salk PL. CD8+ memory T cells require CD4+ T cell help: implication for therapeutic and preventive HIV vaccines. AID Science 2003;3(15) [ http://aidscience.org/articles/aidscience036.asp ].
45. D.J. Shedlock, and H. Shen Requirement for CD4 T cell help in generating functional CD8 T cell memory Science 300 5617 2003 337 339
46. J.C. Sun, and M.J. Bevan Defective CD8 T cell memory following acute infection without CD4 T cell help Science 300 5617 2003 339 342
47. E.M. Janssen, E.E. Lemmens, T. Wolfe, U. Christen, M.G. von Herrath, and S.P. Schoenberger CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes Nature 421 6925 2003 852 856
48. R.S. Corral, and P.B. Petray CpG DNA as a Th1-promoting adjuvant in immunization against Trypanosoma cruzi Vaccine 19 2-3 2000 234 242
49. M.J. McCluskie, R.D. Weeratna, A.M. Krieg, and H.L. Davis CpG DNA is an effective oral adjuvant to protein antigens in mice Vaccine 19 7-8 2000 950 957
50. A. Al-Mariri, A. Tibor, and P. Mertens Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant Infect. Immun. 69 8 2001 4816 4822
51. S. Pal, H.L. Davis, E.M. Peterson, and L.M. de la Maza Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge Infect. Immun. 70 9 2002 4812 4817
52. B.V. Stern, B.O. Boehm, and M. Tary-Lehmann Vaccination with tumor peptide in CpG adjuvant protects via IFN-gamma-dependent CD4 cell immunity J. Immunol. 168 12 2002 6099 6105
53. E. Davila, R. Kennedy, and E. Celis Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade Cancer Res. 63 12 2003 3281 3288
54. Y. Van der Stede, F. Verdonck, S. Vancaeneghem, E. Cox, and B.M. Goddeeris CpG-oligodinucleotides as an effective adjuvant in pigs for intramuscular immunizations Vet. Immunol. Immunopathol. 86 12 2002 31 41
55. T.R. Jones, N. Obaldia, and R.A. Gramzinski Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys Vaccine 17 23-24 1999 3065 3071
56. D. Verthelyi, R.T. Kenney, R.A. Seder, A.A. Gam, B. Friedag, and D.M. Klinman CpG oligodeoxynucleotides as vaccine adjuvants in primates J. Immunol. 168 4 2002 1659 1663
57. H. Xu, S. Wang, F. Guo, R. Lu, and L. Ruan CpG-ODN is a potential candidate adjuvant for human vaccines Zhonghua Yi Xue Za Zhi 82 8 2002 553 556
58. C.L. Cooper, H.L. Davis, and A.M. Krieg Improved hepatitis B vaccine response with CpG ODN 7909 adjuvant Can. J. Infect. Dis. 12 Suppl. B 2001 13
59. N. Dumais, A. Patrick, R.B. Moss, H.L. Davis, and K.L. Rosenthal Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge J. Infect. Dis. 186 8 2002 1098 1105
60. M. Ayash-Rashkovsky, G. Borkow, H. Davis, R.B. Moss, and Z. Bentwich New murine model for HIV-1 infection and rapid vaccine screening Proceedings of the 10th Conference on Retroviruses and Opportunistic Infections Boston, MA 2003 [Abstract #432]
61. I. Lubin, H. Segall, and H. Marcus Engraftment of human peripheral blood lymphocytes in normal strains of mice Blood 83 8 1994 2368 2381
62. C.L. Cooper, H.L. Davis, and M.L. Morris Safe and effective use of CpG as adjuvant for HBV vaccination in HIV infection Proceedings of the 10th Conference on Retroviruses and Opportunistic Infections Boston, MA 2003 [Abstract #400a]